Rajeev Nannapaneni - Natco Pharma CEO Director
| NATCOPHARM | 1,337 13.80 1.02% |
CEO
Rajeev Nannapaneni is CEO Director of Natco Pharma Limited
| Age | 47 |
| Address | Natco House, Hyderabad, India, 500034 |
| Phone | 91 40 2354 7532 |
| Web | https://www.natcopharma.co.in |
Natco Pharma Management Efficiency
The company has return on total asset (ROA) of 0.1889 % which means that it generated a profit of $0.1889 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3123 %, meaning that it generated $0.3123 on every $100 dollars invested by stockholders. Natco Pharma's management efficiency ratios could be used to measure how well Natco Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Natco Pharma's Other Current Assets are increasing as compared to previous years. The Natco Pharma's current Total Current Assets is estimated to increase to about 42.2 B, while Net Tangible Assets are projected to decrease to under 30.4 B.Similar Executives
| Found 2 records | CEO Age | ||
| Jeeben Kurian | TECIL Chemicals and | 32 | |
| Bimal Goculdas | DMCC SPECIALITY CHEMICALS | 56 | |
Management Performance
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.19 |
Natco Pharma Limited Leadership Team
Elected by the shareholders, the Natco Pharma's board of directors comprises two types of representatives: Natco Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Natco. The board's role is to monitor Natco Pharma's management team and ensure that shareholders' interests are well served. Natco Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Natco Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sanivarapu Reddy, Senior Operations | ||
| James Rajakumar, Vice Domestic | ||
| Pavan Bhat, Executive Director | ||
| Nadella Rao, VP Operations | ||
| Bhimavarapu Reddy, Director FDF | ||
| S Rao, Chief Officer | ||
| N Rao, Legal, Affairs | ||
| Rajeev Nannapaneni, CEO Director | ||
| Lakshminarayana, Senior Development | ||
| MS Pharm, MD Director | ||
| Chekuri CS, Company Officer | ||
| Potluri Prasad, Executive Director | ||
| Ravi Namburi, Vice Domestic | ||
| Donthineni MD, President Director |
Natco Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Natco Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.19 | ||||
| Profit Margin | 0.43 % | ||||
| Operating Margin | 0.55 % | ||||
| Current Valuation | 219.45 B | ||||
| Shares Outstanding | 179.11 M | ||||
| Shares Owned By Insiders | 50.90 % | ||||
| Shares Owned By Institutions | 14.56 % | ||||
| Price To Book | 3.38 X | ||||
| Price To Sales | 5.25 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Natco Stock
Natco Pharma financial ratios help investors to determine whether Natco Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Natco with respect to the benefits of owning Natco Pharma security.